# EDGAR Filing Document

**Accession Number:** 0001501697
**File Stem:** 0001628280-25-030743
**Filing Date:** 2025-6
**Character Count:** 7004
**Document Hash:** 70b4d9bc6ae81f06ff33a6b3577063e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-030743.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001628280-25-030743

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** X4 Pharmaceuticals, Inc
- **CENTRAL INDEX KEY:** 0001501697
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273181608
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38295
- **FILM NUMBER:** 251040217

**BUSINESS ADDRESS:**
- **STREET 1:** 61 NORTH BEACON STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02134
- **BUSINESS PHONE:** 857-529-8300

**MAIL ADDRESS:**
- **STREET 1:** 61 NORTH BEACON STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02134

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsanis, Inc.
- **DATE OF NAME CHANGE:** 20100920

?xml version='1.0' encoding='ASCII'? xfor-20250611

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

| | |
|:---|:---|
| **FORM** | **8-K** |

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 11, 2025 (June 9, 2025)**

---

| |
|:---|
| **X4 PHARMACEUTICALS, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delaware** | **001-38295** | **27-3181608** |
| **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

---

| | | |
|:---|:---|:---|
| **61 North Beacon Street,** | **4th Floor** | |
| **Boston,** | **Massachusetts** | &nbsp;&nbsp;**02134** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**(857) 529-8300**

**(Registrant's telephone number, including area code)**

**Not applicable**

**(Former name or former address, if changed since last report)** 

**_______________________________________________________________________________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.001 per share** | **XFOR** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 9, 2025, X4 Pharmaceuticals Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025. As of April 15, 2025, the record date for the Annual Meeting, there were 173,662,376 shares of common stock, par value $0.001 per share, outstanding and entitled to vote. All votes and corresponding numbers in this Current Report on Form 8-K are represented on a pre-reverse stock split basis as of the April 15, 2025 record date of the Annual Meeting, which preceded the April 28, 2025 effective date of the Company's 1-for-30 reverse stock split.

*Proposal 1 - Election of Directors*

The Company's stockholders elected the person listed below as director, to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominees** | **For** | **Withheld** | **Broker Non-Votes** |
| R. Keith Woods | 52,191,014 | 29,872,082 | 53,811,292 |

---

*Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm* 

The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes cast were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 128,889,553 | 6,595,740 | 389,095 |  |

---

*Proposal 3 – Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation* 

The Company's stockholders approved, by a non-binding "say-on-pay" vote, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting. The votes cast were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 67,793,970 | 12,234,847 | 2,034,279 | 53,811,292 |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **X4 PHARMACEUTICALS, INC.** | **X4 PHARMACEUTICALS, INC.** |
| Date: June 11, 2025 | By: | /s/ Adam S. Mostafa |
|  |  | Name: Adam S. Mostafa |
|  |  | Title: Chief Financial Officer |

---